{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:35:15Z","timestamp":1770338115645,"version":"3.49.0"},"reference-count":35,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN\u2010UK\u2010337\u20101981"],"award-info":[{"award-number":["IN\u2010UK\u2010337\u20101981"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Achieving hepatitic C virus (HCV) elimination requires linking people who use drugs (PWUD) into care. We report final direct\u2010acting antivirals (DAAs)\u2010based outcomes from the Integrated\u2010Test\u2010stage \u2010Treat (ITTREAT) study. Project ITTREAT (2013\u20132021), based at an addiction centre, was a \u2018one\u2010stop\u2019 service with innovative linkage to care strategies. Primary outcome was sustained virological response (SVR12) (intention to treat ITT) including whether individuals were recruited in first (period 1) versus last four (period 2 included the COVID\u201019 pandemic) years of the study. Number recruited were <jats:italic>n<\/jats:italic>\u2009=\u2009765, mean age 40.9\u2009\u00b1\u200910.1\u2009years, 78% males, history of current\/past injecting drug use (IDU) and alcohol use being 77% and 90%, respectively. Prevalence of a positive HCV PCR was 84% with 19% having cirrhosis. Comparing those recruited in period 2 versus period 1, there was increasing prevalence of IDU, 90% versus 72% (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001); homelessness, 67% versus 50% (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001); psychiatric diagnosis, 84% versus 50% (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001); overdose history 71% versus 31% (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001), receiving opioid agonist treatment (OAT) 75% versus 52% (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001) and comorbidity 44% versus 25% (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001). Of those treated with DAAs (<jats:italic>n<\/jats:italic>\u2009=\u2009272), ITT SVR rates were 86% (95% CI: 81%\u201390%), being similar in period 2 versus period 1. Predictors of non\u2010SVR were receiving OAT (OR 0.33, 95% CI: 0.12\u20130.87, <jats:italic>p<\/jats:italic>\u2009=\u2009.025) and \u226580% adherence (OR 0.01, 95% CI: 0.003\u20130.041, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001). Reinfection rates period 2 versus period 1 (per 100\u2009person\u2010years) were 1.84 versus 1.70, respectively. In the treated cohort, mortality was 15%, being mostly drug\u2010related. Despite increasing complexity of PWUD, high SVR12 rates are achievable with use of OAT and good adherence.<\/jats:p>","DOI":"10.1111\/jvh.13897","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T07:07:12Z","timestamp":1701241632000},"page":"66-77","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Excellent hepatitis C virus cure rates despite increasing complexity of people who use drugs: Integrated\u2010Test\u2010stage Treat study final outcomes"],"prefix":"10.1111","volume":"31","author":[{"given":"Margaret","family":"O'Sullivan","sequence":"first","affiliation":[{"name":"University Hospitals Sussex NHS Foundation Trust Brighton and Sussex University  Brighton UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna\u2010Marie","family":"Jones","sequence":"additional","affiliation":[{"name":"Sussex Partnership Foundation Trust  Brighton UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adele","family":"Mourad","sequence":"additional","affiliation":[{"name":"University Hospitals Sussex NHS Foundation Trust Brighton and Sussex University  Brighton UK"},{"name":"Brighton &amp; Sussex Medical School  Brighton UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazan","family":"Haddadin","sequence":"additional","affiliation":[{"name":"University Hospitals Sussex NHS Foundation Trust Brighton and Sussex University  Brighton UK"},{"name":"Brighton &amp; Sussex Medical School  Brighton UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7021-8409","authenticated-orcid":false,"given":"Sumita","family":"Verma","sequence":"additional","affiliation":[{"name":"University Hospitals Sussex NHS Foundation Trust Brighton and Sussex University  Brighton UK"},{"name":"Brighton &amp; Sussex Medical School  Brighton UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"World Health Organisation.Global progress report on HIV viral hepatitis and sexually transmitted infections.2021. Accessed November 11 2022.https:\/\/www.who.int\/publications\/i\/item\/9789240027077"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.11.012"},{"key":"e_1_2_10_4_1","unstructured":"UK Health Security Agency.Hepatitis C in the UK 2023. Working to eliminate hepatitis C as a public health problem. Accessed February 03 2023.https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1133731\/hepatitis\u2010c\u2010in\u2010the\u2010UK\u20102023.pdf"},{"key":"e_1_2_10_5_1","unstructured":"UK Health Security Agency.Hepatitis C in England 2022 Working to eliminate hepatitis C as a public health problem. Accessed November 03 2022.https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1057271\/HCV\u2010in\u2010England\u20102022\u2010full\u2010report.pdf"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-021-01625-w"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.05.028"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.07.002"},{"key":"e_1_2_10_9_1","unstructured":"World Health Organization.Global health sector strategy on viral hepatitis 2016\u20102021.Towards Ending Viral hepatitis.2016. Accessed February 15 2017.http:\/\/apps.who.int\/iris\/bitstream\/10665\/246177\/1\/WHO\u2010HIV\u20102016.06\u2010eng.pdf?ua=1"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14779"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.07.042"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14403"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13214"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1463423617000731"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.11.018"},{"issue":"3","key":"e_1_2_10_16_1","first-page":"S90","article-title":"Non\u2010invasive evaluation of liver fibrosis in hepatitis C","volume":"32","author":"L\u00e9dinghen V","year":"2008","journal-title":"Gastroenterol Clin Biol"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa571"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa253"},{"key":"e_1_2_10_19_1","unstructured":"Office of National Statistics.Alcohol\u2010specific deaths in the UK: registered in 2020. Accessed September 07 2022.https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/causesofdeath\/bulletins\/alcoholrelateddeathsintheunitedkingdom\/registeredin2020"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2021.306256"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00471-4"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103588"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00397-6"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003653"},{"key":"e_1_2_10_25_1","unstructured":"European Centre for Disease Prevention and Control.Models of good practice for community\u2010based testing linkage to care and adherence to treatment for hepatitis B and C HIV and tuberculosis and for helath promotion interventions to prevent infections among people who inject drugs. Accessed May 30 2023.https:\/\/www.ecdc.europa.eu\/en\/publications\u2010data\/models\u2010good\u2010practice\u2010community\u2010based\u2010testing\u2010linkage\u2010care\u2010and\u2010adherence\u2010treatment"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30304-2"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12611"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1715"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab334"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1089"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002041"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa612"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13574"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15210"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15229"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103286"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T06:54:23Z","timestamp":1705906463000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1111\/jvh.13897"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13897","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,28]]},"assertion":[{"value":"2023-06-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}